Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Gregory Frost

Halozyme Therapeutics, Inc.

Aurigene Oncology is a clinical stage biotech company focused on the discovery and development of novel and effective therapeutics for the treatment of cancer. They leverage expertise in oncology to benefit cancer patients worldwide.

Aurigene Oncology

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. 

We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. 

We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details.   

We are Halozyme. 



Silicon Valley Bank

Oxford Finance LLC

Pharmakon Advisors

Athyrium Capital Management LP

Janssen Biotech

argenx

Halozyme, Inc.

We are excited to announce that Halozyme and Acumen Pharmaceuticals, Inc. have entered a global collaboration and non-exclusive license agreement for the ENHANZE® technology in Alzheimer’s disease.

This partnership presents an exceptional opportunity to provide additional treatment options to patients with Alzheimer's disease. According to the World Health Organization, over 55 million people suffer from dementia worldwide, and Alzheimer's disease can be attributed to 60-70% of cases. 

Our collaboration reinforces our commitment to provide innovative solutions to improve the patient treatment experience, particularly for such a challenging disease in a large patient population.

https://ow.ly/Hyyl50Q65fy

Halozyme recently reported our third quarter 2023 financial and operating results, including a 15% year-over-year increase in royalty revenue to a record $114.4 million.

"The third quarter was remarkable, with multiple, meaningful, de-risking events and progress for our upcoming series of Wave 3 potential product launches, projected for 2023-2025. I am also pleased with the progress in advancing discussions on development of our HVAI." - Dr. Helen Torley, president and CEO of Halozyme.

We are delighted with our strong operating performance and expense management throughout the year and will continue to work toward achieving our 2023 financial and operational goals.

#Halozyme

https://ow.ly/sFcF50Q659y

Join us and our men’s health experts on Friday, November 17, 2023, for a live product theater at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting in San Diego to learn about different auto-injection and oral delivery testosterone replacement therapy options. 

We hope to see you there! 

#Halozyme #SMSNA23 #TRT #MensHealth

Subcutaneous (SC) infusion is a promising way to deliver drugs, but the volume and viscosity of solutions that can be administered subcutaneously are limited by the inability of fluids to flow in the SC space. 

Recent research looks a little closer at how recombinant human hyaluronidase PH20 (rHuPH20) can help overcome volume and time constraints associated with SC administrations across various concentrations.

Read the research here: https://bit.ly/46KpdUW

#Subcutaneous #DrugDelivery


Halozyme aims to innovate in delivery technology for transformative therapies. 

With innovation and dedication, our mission includes simplifying treatment procedures and reducing the time required for therapies, with subcutaneous drug delivery. 

Through our efforts, Halozyme aims to empower both healthcare providers and patients by providing potentially life-changing drug delivery solutions. 

https://bit.ly/3LYJka5

#Halozyme #subcutaneousdrugdelievry

Metric
Company Name	Halozyme Therapeutics, Inc.	Aurigene Oncology	FiercePharma	Idorsia Ltd
Symbol	HALO			IDIA
MSH ID	COM:HALOZYME	COM:AURIGENE	COM:FIERCEPHARMA	COM:IDORSIA
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	IN	US	CH
Stage				Post-IPO Debt
Employee Count	373			636
Website	halozyme.com	aurigene.com	fiercepharma.com	idorsia.com
LinkedIn	halozyme-therapeutics-inc-
Founders

Metric
Market Cap	6.74B			311.77M
Enterprise Value
Monthly Web Traffic	7.62K	15.55K	484.53K	19.83K
Web Traffic Growth	-0.80	11.26	-0.10	1.09
Valuation
Raised Capital				83.54M

Metric
Revenue	829.25M	173.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	636.89M	143.86M
EBITDA	422.43M	-597.34M
Operating Income	337.57M	-619.04M
Net Income	281.59M	-339.61M
EPS	2.13	-1.90
Diluted EPS	2.10	-1.90
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.79	0.95
Operating Profit Margin	0.46	-0.52
EBITDA Margin	0.51	-3.44
Net Profit Margin	0.39	0.31
Return on Equity	2.05	0.44
Return on Assets	0.17	0.06
Return on Capital Employed	0.22	-0.29

COM:HALOZYME

Halozyme Therapeutics, Inc.

Last Close

45.70

22/11 21:00

Market Cap

6.74B

Beta: -

Volume Today

4.55M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	17.53	-0.73
P/B Ratio	17.86	-0.33
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.34	4.46
EV Multiple	14.08	14.37

Metric
Days Sales Outstanding	101.60	52.13
Days Payables Outstanding	38.70	751.10
Days Inventory Outstanding	331.59	2.47K
Operating Cycle	414.45	2.52K
Cash Conversion Cycle	388.24	1.77K
Asset Turnover	0.48	0.28

Metric
Operating Cash Flow	388.57M	-717.35M
Free Cash Flow	373.28M	-728.06M
Cash Flow to Debt	0.29	-0.35
Operating Cash Flow/Sales	0.50	-3.00
Free Cash Flow Yield	0.08	-2.60

Metric
Cash & Equivalents	118.37M	165.35M
Accounts Receivable	-3.34M	-14.68M
Inventory	127.60M	67.42M
Goodwill	416.82M
Debt to Capitalization	0.95	11.32
Debt to Assets	0.79	1.85
Current Ratio	7.63	1.21
Quick Ratio	6.21	1.00

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.04	0.18
R&D to Revenue	0.10	1.94
SG&A to Revenue		4.00